Pfizer and BioNTech Dose First Participants in the U.S.
Hey fellow Traders from TradingView, this is an update to the actual Situation and my previous Analysis
If you agree with my Analysis or find it useful , please leave me a like for my work it would be greatly appreciated.
Im still bullish and optimistic that BNTX participation will have a huge global impact. The stock seems to be news related, so expect it to make huge moves when they finally will announce to have completed those first worldwide clinical studies.
The Moving Averages are lining up and signalizing us there will soon be a Price expansion.
Assuming the 55 MA line serves as a support we cacn expect the stock to bounce off that and rise to the resistance battleground area.
I´d place my Stop Loss below the next support pivot at either 36.85 to not risk gettiong shaken out before the upcoming outbreak. If you can handle that amount of risk.
If not a LOD SL is always a great way to reduce risk.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. This U.S. trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.
"The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates, and is to be evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S. will enroll up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with a given dose level of a vaccine candidate once testing of that candidate and dose level in younger adults has provided initial evidence of safety and immunogenicity. Sites currently dosing participants include NYU Grossman School of Medicine and the University of Maryland School of Medicine. The University of Rochester Medical Center/Rochester Regional Health and Cincinnati Children’s Hospital Medical Center will begin enrollment shortly."
Source by:
BNTX
22UA
investors.biontech.d...us-part-global-covid
Remember, this is only my opinion after considering all facts and informing myself about the Up/Downside of this stock.
So no financial advise is given here. Always do your own reasearch.
Thank you for taking the time and i hope to see you again in my next post!
See you there
Sincerly,
Sebastian - TradingExperts Europe
If you agree with my Analysis or find it useful , please leave me a like for my work it would be greatly appreciated.
Im still bullish and optimistic that BNTX participation will have a huge global impact. The stock seems to be news related, so expect it to make huge moves when they finally will announce to have completed those first worldwide clinical studies.
The Moving Averages are lining up and signalizing us there will soon be a Price expansion.
Assuming the 55 MA line serves as a support we cacn expect the stock to bounce off that and rise to the resistance battleground area.
I´d place my Stop Loss below the next support pivot at either 36.85 to not risk gettiong shaken out before the upcoming outbreak. If you can handle that amount of risk.
If not a LOD SL is always a great way to reduce risk.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. This U.S. trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.
"The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates, and is to be evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S. will enroll up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with a given dose level of a vaccine candidate once testing of that candidate and dose level in younger adults has provided initial evidence of safety and immunogenicity. Sites currently dosing participants include NYU Grossman School of Medicine and the University of Maryland School of Medicine. The University of Rochester Medical Center/Rochester Regional Health and Cincinnati Children’s Hospital Medical Center will begin enrollment shortly."
Source by:
BNTX
22UA
investors.biontech.d...us-part-global-covid Remember, this is only my opinion after considering all facts and informing myself about the Up/Downside of this stock.
So no financial advise is given here. Always do your own reasearch.
Thank you for taking the time and i hope to see you again in my next post!
See you there
Sincerly,
Sebastian - TradingExperts Europe
Related Ideas
